{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:48:12Z","timestamp":1754153292813,"version":"3.41.2"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1111\/igc.0b013e3181a12eb9","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:30:18Z","timestamp":1291383018000},"page":"343-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?"],"prefix":"10.1016","volume":"19","author":[{"given":"Carolyn","family":"McCourt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybil","family":"Dessie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Brard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don S.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0005","first-page":"43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0010","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0015","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1040-8428(99)00049-9","article-title":"Role of chemotherapy in relapsed ovarian cancer","volume":"32","author":"Colombo","year":"1999","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0040","first-page":"610","article-title":"Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer","volume":"21","author":"Wilailak","year":"2000","journal-title":"Eur J Gynaecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0045","first-page":"837","article-title":"Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum","volume":"2","author":"Kavanagh","year":"1996","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ygyno.2003.12.002","article-title":"The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer","volume":"92","author":"Kita","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0060","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","article-title":"Docetaxel for patients with paclitaxel-resistant mullerian carcinoma","volume":"18","author":"Verschraegen","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ijgc-00009577-200303000-00007","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0070","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single agent paclitaxel in platinum\/paclitaxel refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0075","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80mg\/m2) in platinum and paclitaxel resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0080","unstructured":"Rustin GJ, Quinn M, du Bois A, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Available at: http:\/\/ctep.cancer.gov\/resources\/gcig\/jncirustin.pdf."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0090","first-page":"798","article-title":"Re-treatment of patients with recurrent epithelial ovarian cancer with platinum-based chemotherapy","volume":"73","author":"Gershenson","year":"1989","journal-title":"Obstet Gynecol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0090-8258(85)90249-5","article-title":"Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent","volume":"21","author":"Seltzer","year":"1985","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0105","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0110","first-page":"S15-62","article-title":"Salvage weekly paclitaxel in recurrent ovarian cancer","volume":"24","author":"Abu-Rustum","year":"1997","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/gyno.2000.5958","article-title":"Treatment of relapsed carcinoma of the ovary with single agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy","volume":"79","author":"Zanotti","year":"2000","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0120","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess responses to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0125","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0130","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann Oncol."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0135","first-page":"833","article-title":"Salvage therapy for ovarian cancer","volume":"12","author":"Sabbatini","year":"1998","journal-title":"Oncology (Williston Park)"},{"issue":"suppl 2","key":"10.1111\/IGC.0b013e3181a12eb9_bb0140","first-page":"644","article-title":"Mechanisms of drug resistance in ovarian cancer","volume":"71","author":"Johnson","year":"1993","journal-title":"Cancer."},{"key":"10.1111\/IGC.0b013e3181a12eb9_bb0145","first-page":"188","article-title":"Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer","volume":"17","author":"Tresukosol","year":"1996","journal-title":"Eur J Gynaecol Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181a12eb9","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181a12eb9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:17:25Z","timestamp":1753222645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24026963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1048891X24026963"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181a12eb9","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181a12eb9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 IGCS and ESGO","name":"copyright","label":"Copyright"}]}}